Newsroom

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

GALASHIELS E MARLOW, REINO UNIDO--(BUSINESS WIRE)--A Kyowa Kirin International, subsidiária integral da Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), anunciou hoje a assinatura de um contrato de distribuição exclusiva com a Knight Therapeutics (“Knight”) (TSX: GUD) para distribuição de mogamulizumabe em países selecionados da América Latina. Nos termos do contrato, a Knight será responsável por obter as aprovações regulatórias necessárias e comercializar o mogamulizumabe para micose fungoide (...

GALASHIELS e MARLOW, Regno Unito--(BUSINESS WIRE)--Kyowa Kirin International, società interamente controllata da Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), oggi ha annunciato la firma di un accordo di distribuzione esclusiva con Knight Therapeutics (“Knight”) (TSX: GUD) per la distribuzione di mogamulizumab in determinati Paesi dell'America Latina. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unic...

GALASHIELS y MARLOW, Reino Unido--(BUSINESS WIRE)--Kyowa Kirin International, subsidiaria de propiedad absoluta de Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin), anunció hoy la firma de un acuerdo exclusivo de distribución con Knight Therapeutics (“Knight”) (TSX: GUD) para comercializar mogamulizumab en determinados países de América Latina. En virtud del acuerdo, Knight será responsable de obtener las autorizaciones regulatorias necesarias y de comercializar mogamulizumab para el tratamiento...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx Europe Infrastructure UCITS ETF 30.09.2026 FTEI.LN IE000TIZ5AP4  300,002.00 EUR   6,200,335.39   20.668  ...

GALASHIELS & MARLOW, VK--(BUSINESS WIRE)--Kyowa Kirin International, een volledige dochteronderneming van Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), heeft vandaag de ondertekening aangekondigd van een exclusieve distributieovereenkomst met Knight Therapeutics ('Knight') (TSX: GUD) voor de distributie van mogamulizumab in geselecteerde landen in Latijns-Amerika. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden ver...

GALASHIELS et MARLOW, Royaume-Uni--(BUSINESS WIRE)--Kyowa Kirin International, filiale à 100 % de Kyowa Kirin Co., Ltd. (TSE : 4151, Kyowa Kirin), a annoncé aujourd’hui avoir signé un accord de distribution exclusif avec Knight Therapeutics (« Knight ») (TSX : GUD) portant sur la distribution du mogamulizumab dans certains pays d’Amérique latine. Selon les termes de l’accord, Knight aura pour mission d’obtenir les autorisations réglementaires nécessaires pour commercialiser le mogamulizumab en...

GALASHIELS & MARLOW, GB--(BUSINESS WIRE)--Kyowa Kirin International, eine hundertprozentige Tochtergesellschaft der Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), gab heute die Unterzeichnung einer exklusiven Vertriebsvereinbarung mit Knight Therapeutics („Knight“) (TSX: GUD) über den Vertrieb von Mogamulizumab in ausgewählten Ländern Lateinamerikas bekannt. Gemäß den Vertragsbedingungen ist Knight dafür verantwortlich, die erforderlichen behördlichen Genehmigungen einzuholen und Mogamulizumab...

CHEVY CHASE, Md.--(BUSINESS WIRE)--Forbright, Inc. (Nasdaq: FRBT) (the "Company"), the parent company of wholly-owned subsidiary Forbright Bank, has scheduled the release of its third quarter 2026 financial results for Thursday, October 29, 2026, at approximately 6:00 a.m. ET. The earnings press release and investor presentation will be available on the Company’s Investor Relations website at ir.forbrightbank.com. Forbright, Inc. will host a conference call at 8:00 a.m. ET on October 29, 2026,...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...